文献速递妇科

异常错配修复及其他临床病理因素预测年轻女性复杂性不典型增生和髙分化子宫内膜腺癌对孕激素治疗反应不佳:一项连续病例系列研究

Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
PubMed 文献 · BJOG · 2017-01-27

该连续病例系列研究纳入84例≤55岁的复杂性不典型增生(CAH)或FIGO 1级子宫内膜腺癌(FIGO 1 EAC)患者,评估孕激素治疗反应与包括错配修复(MMR)蛋白免疫组化在内的临床病理因素的关系。6例(7%)MMR免疫组化异常,其中5例(83%)初诊为FIGO 1 EAC;MMR异常者孕激素治疗后无病变消退,而MMR正常者41例(53%)消退(P=0.028)。年龄≤40岁和初始病变类型(CAH vs FIGO 1 EAC)是孕激素反应的预测因素,BMI不是。

要点

  • ≤55岁CAH或FIGO 1 EAC患者中7%存在MMR蛋白免疫组化异常。
  • MMR异常者孕激素治疗后无病变消退,正常者53%消退(P=0.028)。
  • 年龄≤40岁和初始病变类型(CAH vs FIGO 1 EAC)预测孕激素反应。

核心结论

  • 在该队列中,7%的≤55岁CAH或FIGO 1 EAC女性存在MMR蛋白免疫组化缺失,这些患者侵袭性癌发生率更高且孕激素治疗后病变消退率更低。

研究设计与样本

  • 连续病例系列,纳入84例≤55岁的CAH或FIGO 1 EAC患者,评估基于年龄、BMI、初始组织学和MMR蛋白免疫组化染色的孕激素治疗反应。

主要发现

  • 6例(7%)患者免疫组化染色异常,其中5例(83%)初诊为FIGO 1 EAC。
  • 孕激素治疗后,MMR蛋白免疫组化异常患者的子宫内膜病变均未消退(增生或恶性均未消退),而免疫组化正常者中41例(53%)消退(P=0.028)。
  • 年龄≤40岁和初始病变(CAH vs FIGO 1 EAC)是孕激素反应的预测因素,BMI不是。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the response to progestin therapy in young women with endometrial complex atypical hyperplasia (CAH) or FIGO grade 1 endometrial adenocarcinoma (FIGO 1 EAC) based on clinicopathologic features, including abnormal DNA mismatch repair (MMR) by immunohistochemistry (IHC). DESIGN: Consecutive case series. SETTING: Olive View-UCLA Medical Center in Sylmar, CA, USA, and Cedars-Sinai Medical Center in Los Angeles, CA, USA. POPULATION: Women ≤55 years old with CAH or FIGO 1 EAC. METHODS: Response to progestin therapy in 84 consecutive patients was assessed based on clinicopathologic factors, including age, body mass index (BMI), initial histology, and IHC staining for MMR proteins. MAIN OUTCOME MEASURES: Rates of abnormal MMR protein expression and response to progestin therapy were determined. RESULTS: Six (7%) patients had abnormal IHC staining, of whom five (83%) had FIGO 1 EAC at initial diagnosis. Following progestin treatment, none of the endometrial lesions in patients with abnormal IHC for MMR proteins had resolution of hyperplasia or malignancy, in contrast to 41 (53%) with normal staining (P = 0.028). Age ≤40 years and initial lesion (CAH versus FIGO 1 EAC) were predictors of response to progestin; BMI was not. CONCLUSIONS: In this cohort, 7% of women ≤55 years of age with CAH or FIGO 1 EAC had loss of MMR proteins by IHC. These patients had a higher incidence of invasive cancer and a lower incidence of resolution with progestin therapy. TWEETABLE ABSTRACT: Abnormal MMR protein expression predicts poor response to progestins in young women with CAH or FIGO 1 EAC.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Zakhour M, Cohen JG, Gibson A, et al. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series. BJOG. 2017. PMID: 28128512. doi:10.1111/1471-0528.14491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。